Stay updated on Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page
- Check3 days agoChange DetectedAdded access to the Study Protocol and Statistical Analysis Plan PDFs in the Study Documents section, along with associated metadata such as file size and upload dates.SummaryDifference72%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page now shows an updated Revision tag (v3.6.4), replacing the prior revision (v3.6.3) in the page metadata.SummaryDifference0.0%

- Check47 days agoChange DetectedA new revision tag 'Revision: v3.6.3' was added, replacing the previous 'Revision: v3.6.0' tag to indicate an updated patch version on the page.SummaryDifference0.0%

- Check61 days agoChange DetectedNew guidance sections were added to help readers read the study record and understand how to join. The recruitment status was updated to No longer looking for participants, indicating enrollment has closed.SummaryDifference0.3%

- Check68 days agoChange DetectedRevision tag for the study documents updated from v3.5.4 to v3.5.5. This reflects an updated version of the documents referenced on the page.SummaryDifference0.0%

- Check82 days agoChange DetectedPublication details for a PubMed-listed article related to the study were added under Publications, including authors, title, journal, year, and DOI. A note explains that some entries are auto-filled from PubMed and may not be exclusively about the study.SummaryDifference0.2%

Stay in the know with updates to Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.